Key result
Cardiovascular AI achieves routine clinical implementation in only ~14% of studies, with most remaining in validation.
Why the study?
Although AI is transforming cardiovascular medicine, the clinical implementation of these technologies remains poorly characterised.
What is the current landscape and implementation maturity of artificial intelligence applications in cardiovascular medicine?
Systematic Review (n=74)
What is the current landscape and implementation maturity of artificial intelligence applications in cardiovascular medicine?
Despite promising diagnostic and prognostic performance, most AI applications in cardiovascular medicine remain at the validation stage, with only 13.5% achieving routine clinical implementation.
Answers are grounded in this paper and cite their sources.
Most cardiovascular AI tools remain unproven in routine practice; leaves open the need for implementation-focused trials before clinical adoption.
Artificial intelligence (AI) is transforming cardiovascular medicine through applications in disease detection, diagnosis, risk prediction, and clinical decision support. However, the clinical implementation of these technologies remains poorly characterised. This systematic review evaluated the current landscape of AI applications in cardiovascular medicine, focusing on implementation maturity and clinical translation. The review followed PRISMA guidelines and a prospectively registered PROSPERO protocol. Data extraction included study characteristics, cardiovascular domain, AI methodology, clinical application, validation strategy and implementation maturity, assessed using a predefined five-level framework. AI methodologies were classified as conventional machine learning, deep learning, hybrid ML/deep learning, multimodal AI, or large language models/generative AI. Seventy-four studies met the eligibility criteria. Conventional machine learning was the most frequently used methodology (47.3%), followed by deep learning (41.9%), whereas multimodal AI (5.4%), hybrid ML/deep learning (2.7%), and large language models/generative AI (2.7%) were uncommon. Applications focused mainly on screening and early detection (31.1%), risk stratification and prognosis (25.7%), treatment planning (16.2%), diagnosis (13.5%), and monitoring (12.2%). Most studies reached implementation maturity Level 3 (clinical validation, 47.3%) or Level 2 (technical validation, 35.1%), while only 13.5% achieved routine clinical implementation (Level 5) and 4.1% reached clinical deployment (Level 4). Although AI demonstrated promising diagnostic and prognostic performance across multiple cardiovascular conditions, most applications remain at the validation stage. Future research should prioritise implementation science, pragmatic evaluation, and real-world evidence to facilitate routine adoption and maximise patient benefit and healthcare value.
No takes yet. Share an insight, caveat, or question.
Osoro et al. (2026) conducted a systematic review in Cardiovascular conditions (n=74). Artificial intelligence was evaluated on Implementation maturity and clinical translation. Among 74 studies of AI in cardiovascular medicine, only 13.5% achieved routine clinical implementation, with most remaining at the clinical (47.3%) or technical (35.1%) validation stage.
Synapse has enriched 10 related papers. Consider them for comparative context: